What is the CVR number of CONTERA PHARMA A/S?

CONTERA PHARMA A/S is registered with CVR / Virk under CVR 33062214.

What is the revenue of CONTERA PHARMA A/S?

CONTERA PHARMA A/S reported revenue of DKK 20,6M in 2025.

CONTERA PHARMA A/S employs 21 people as of the latest annual report.

Mikael Søndergaard Thomsen is Management of CONTERA PHARMA A/S, in role since 2010.

Joseph Donald deBethizy chairs the board of CONTERA PHARMA A/S, in role since 2013.

CONTERA PHARMA A/S's registered address is Venlighedsvej 4.

A/SActive

CVR 33062214Venlighedsvej 4, 2970 HørsholmResearch and experimental development on natural sciences and engineering · NACE 7210Est. 2010 · 15 years old21 employeeswww.conterapharma.com

Actively employed in the business

Name	Role	Member since
Current (1)
TN Thomas Nikolaj Sager Chief Executive Officer	Chief Executive Officer	2020
Former (2)
MS Mikael Søndergaard Thomsen Management	Management	2010 – 2018
JB John Bondo Hansen Chief Executive Officer	Chief Executive Officer	2010 – 2020

Non-executive oversight

Name	Role	Member since
Current (5)
JH Jee Hun Kim	Board of Directors	2026
MM Mahmoud Mahmoudian	Board of Directors	2024
PE Paul Ejnar Gremaud Kristjansen	Board of Directors	2024
MC Mi Chung Ahn	Chairman	2026
JY Jae Young Lee	Board of Directors	2023
Former (14)
BG Bobby G Soni	Board of Directors	2011 – 2014
EJ Eun Ju Kim	Board of Directors	2020 – 2022
GM Gunnar Magnus Severus Modee Persson	Board of Directors	2012 – 2014
JY Jung Yoon Um	Board of Directors	2019 – 2021
SY Soo Yeon Park	Board of Directors	2024 – 2025
FK Frank Knudsen	Board of Directors	2011 – 2012
SH Sang Hoon Kim	Board of Directors	2014 – 2020
CS Carsten Schou	Board of Directors	2012 – 2014
JD Joseph Donald deBethizy	Chairman	2013 – 2014
SH Sun Ho Kim	Board of Directors	2021 – 2023
WL WooHyun Lee	Chairman	2023 – 2026
ES Else Sissel Vorstrup	Board of Directors	2013 – 2014
SJ Sung Joon Kim	Board of Directors	2022 – 2023
HW Hee Won Yoo	Chairman	2014 – 2023

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Bukwang Pharmaceutical Co., Ltd	Individual	90–99.99%	90–99.99%	2024
Medici 2020-1 Private Equity Fund	Individual	25–33.32%	25–33.32%	2020

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.